Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.

Dozens of Massachusetts biotech leaders will be heading to San Francisco this upcoming week for the 2025 J.P. Morgan ...

Among significant news last week, the US Food and Drug Administration (FDA) required Agios Pharmaceuticals to amend the label ...

Bloom Burton analyst David Martin PhD has maintained their neutral stance on RPTX stock, giving a Hold rating on January 10.Stay Ahead of the ...